Substantial attributable risk related to a functional mu-opioid receptor gene polymorphism in association with heroin addiction in central Sweden.
paper
Cited
Public
Unavailable
- Authors
- Bart, G; Heilig, M; LaForge, K S; Pollak, L; Leal, S M; Ott, J; Kreek, M J
- Year
- 2004
- Journal
- Molecular psychiatry
- PMID
- 15037869
- DOI
- 10.1038/sj.mp.4001504
- PMCID
- PMC6141020
No figures extracted from this document.
No chunks β full text not yet ingested.
No entities extracted from this document yet.
No uploaded files.
Not in any collection.
No citations found.
In this knowledge base
External
| Title | Authors | Journal | Year | Link |
|---|---|---|---|---|
| Molecular and cellular basis of mu-opioid receptor signaling: mechanisms underlying tolerance and dependence development. | Swingler M et al. | β | 2025 | β |
| Opioid Use Disorders: Prevention, Diagnosis, and Treatment Strategies to Mitigate Addiction Risks. | Agarwal U et al. | β | 2025 | β |
| Molecular and Environmental Determinants of Addictive Substances. | Lorek M et al. | β | 2024 | β |
| Pharmacogenetics of Biochemically Verified Abstinence in an Opioid Agonist Therapy Randomized Clinical Trial of Methadone and Buprenorphine/Naloxone. | Kazi I et al. | β | 2024 | β |
| Genetic and epigenetic studies of opioid abuse disorder - the potential for future diagnostics. | Abdulmalek S et al. | β | 2023 | β |
| Oxycodone: A Current Perspective on Its Pharmacology, Abuse, and Pharmacotherapeutic Developments. | Barrett JE et al. | β | 2023 | β |
| Investigating the potential of mirtazapine to induce drug-seeking behavior in free-choice drinking mouse model. | Althobaiti YS | β | 2022 | β |
| Mu opioid receptor gene variant modulates subjective response to smoked cannabis. | Bourgault Z et al. | β | 2022 | β |
| Nicotine and opioid co-dependence: Findings from bench research to clinical trials. | Custodio L et al. | β | 2022 | β |
| Pharmacogenetics of Addiction Therapy. | Graham DP et al. | β | 2022 | β |
| [Genetics and pain: approach and implications in clinical practice]. | Montero AA et al. | β | 2021 | β |
| Genetic Vulnerability to Opioid Addiction. | Reed B et al. | β | 2021 | β |
| Investigating the CYP2B6 rs3745274 and rs3211371 polymorphisms in Methadone-Responder and Non-Responder Addicts in Iran. | Sadat Aghabozorg Afjeh S et al. | β | 2021 | β |
| The molecular neurobiology and neuropathology of opioid use disorder. | Blackwood CA et al. | β | 2021 | β |
| Genome-Wide Association Study of Opioid Cessation. | Cox JW et al. | β | 2020 | β |
| Murine model of OPRM1 A118G alters oxycodone self-administration and locomotor activation, but not conditioned place preference. | Collins D et al. | β | 2020 | β |
| Pharmacogenomics of Pain Management: The Impact of Specific Biological Polymorphisms on Drugs and Metabolism. | Cornett EM et al. | β | 2020 | β |
| Relapse-like behavior in a mouse model of the OPRM1 (mu-opioid receptor) A118G polymorphism: Examination with intravenous oxycodone self-administration. | Zhang Y et al. | β | 2020 | β |
| The Streetlight Effect: Reappraising the Study of Addiction in Light of the Findings of Genome-wide Association Studies. | Hall FS et al. | β | 2020 | β |
| What's new in chronic pain pathophysiology. | Cohen I et al. | β | 2020 | β |
| Current status of opioid addiction treatment and related preclinical research. | Kreek MJ et al. | β | 2019 | β |
| Current understanding of the neurobiology of opioid use disorder: An overview. | Moningka H et al. | β | 2019 | β |
| Molecular Imaging of Opioid and Dopamine Systems: Insights Into the Pharmacogenetics of Opioid Use Disorders. | Burns JA et al. | β | 2019 | β |
| Implication of OPRM1 A118G Polymorphism in Opioids Addicts in Pakistan: In vitro and In silico Analysis. | Ahmed M et al. | β | 2018 | β |
| Involvement of Activated Brain Stress Responsive Systems in Excessive and "Relapse" Alcohol Drinking in Rodent Models: Implications for Therapeutics. | Zhou Y et al. | β | 2018 | β |
| Molecular Genetics and New Medication Strategies for Opioid Addiction. | Hurd YL et al. | β | 2018 | β |
| Opioid receptors: drivers to addiction? | Darcq E et al. | β | 2018 | β |
| Opioid Receptors Gene Polymorphism and Heroin Dependence in Iran. | Soleimani Asl S et al. | β | 2018 | β |
| Oprm1 A112G, a single nucleotide polymorphism, alters expression of stress-responsive genes in multiple brain regions in male and female mice. | Collins D et al. | β | 2018 | β |
| Association of Variants of Arginine Vasopressin and ArginineΒ Vasopressin Receptor 1A With Severe AcetaminophenΒ Liver Injury. | Randesi M et al. | β | 2017 | β |
| The ΞΌ-opioid receptor nonsynonymous variant 118A>G is associated with prolonged abstinence from heroin without agonist treatment. | Levran O et al. | β | 2017 | β |
| Morphine-induced antinociception and reward in "humanized" mice expressing the mu opioid receptor A118G polymorphism. | Henderson-Redmond AN et al. | β | 2016 | β |
| Variants of opioid system genes are associated with non-dependent opioid use and heroin dependence. | Randesi M et al. | β | 2016 | β |
| Mouse model of the OPRM1 (A118G) polymorphism: differential heroin self-administration behavior compared with wild-type mice. | Zhang Y et al. | β | 2015 | β |
| Alcohol: a stimulant activating brain stress responsive systems with persistent neuroadaptation. | Zhou Y et al. | β | 2014 | β |
| Association of OPRD1 polymorphisms with heroin dependence in a large case-control series. | Nelson EC et al. | β | 2014 | β |
| Epigenetically modified nucleotides in chronic heroin and cocaine treated mice. | Chao MR et al. | β | 2014 | β |
| Genetics of opiate addiction. | Reed B et al. | β | 2014 | β |
| Genetics of Opioid Dependence: A Review of the Genetic Contribution to Opioid Dependence. | Mistry CJ et al. | β | 2014 | β |
| Introduction to deep sequencing and its application to drug addiction research with a focus on rare variants. | Wang S et al. | β | 2014 | β |
| Mu opioid receptor gene: new point mutations in opioid addicts. | Dinarvand A et al. | β | 2014 | β |
| Pharmacogenetics of addiction therapy. | Nielsen DA et al. | β | 2014 | β |
| Association of polymorphisms in pharmacogenetic candidate genes (OPRD1, GAL, ABCB1, OPRM1) with opioid dependence in European population: a case-control study. | Beer B et al. | β | 2013 | β |
| Case-control association analysis of polymorphisms in the Ξ΄-opioid receptor, OPRD1, with cocaine and opioid addicted populations. | Crist RC et al. | β | 2013 | β |
| Case-control association study of WLS variants in opioid and cocaine addicted populations. | Crist RC et al. | β | 2013 | β |
| Consequences of the 118A>G polymorphism in the OPRM1 gene: translation from bench to bedside? | Mura E et al. | β | 2013 | β |
| Dopamine receptor D1 and postsynaptic density gene variants associate with opiate abuse and striatal expression levels. | Jacobs MM et al. | β | 2013 | β |
| Implications of genome wide association studies for addiction: are our a priori assumptions all wrong? | Hall FS et al. | β | 2013 | β |
| Mu-opioid receptor A118G polymorphism in healthy volunteers affects hypothalamic-pituitary-adrenal axis adrenocorticotropic hormone stress response to metyrapone. | Ducat E et al. | β | 2013 | β |
| Mu opioids and their receptors: evolution of a concept. | Pasternak GW et al. | β | 2013 | β |
| Novel pharmacotherapeutic strategies for treatment of opioid-induced neonatal abstinence syndrome. | McLemore GL et al. | β | 2013 | β |
| Opioid therapy pharmacogenomics for noncancer pain: efficacy, adverse events, and costs. | Xu Y et al. | β | 2013 | β |
| OPRM1 rs1799971 polymorphism and opioid dependence: evidence from a meta-analysis. | Haerian BS et al. | β | 2013 | β |
| Peter Riederer "70th birthday" neurobiological foundations of modern addiction treatment. | Jacob C | β | 2013 | β |
| Shared and unique genetic contributions to attention deficit/hyperactivity disorder and substance use disorders: a pilot study of six candidate genes. | Carpentier PJ et al. | β | 2013 | β |
| A118G mu opioid receptor polymorphism among drug addicts in Malaysia. | Nagaya D et al. | β | 2012 | β |
| A common single nucleotide polymorphism A118G of theΒ ΞΌ opioid receptor alters its N-glycosylation and protein stability. | Huang P et al. | β | 2012 | β |
| Association of polymorphisms of the mu opioid receptor gene with the severity of HIV infection and response to HIV treatment. | Proudnikov D et al. | β | 2012 | β |
| Association study of the Ξ²-arrestin 2 gene (ARRB2) with opioid and cocaine dependence in a European-American population. | Ambrose-Lanci LM et al. | β | 2012 | β |
| Common and specific liability to addiction: approaches to association studies of opioid addiction. | Nielsen DA et al. | β | 2012 | β |
| Direct-to-consumer genetic testing for addiction susceptibility: a premature commercialisation of doubtful validity and value. | Mathews R et al. | β | 2012 | β |
| Genetic-epigenetic interaction modulates ΞΌ-opioid receptor regulation. | Oertel BG et al. | β | 2012 | β |
| Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics. | Kreek MJ et al. | β | 2012 | β |
| The genetics of substance dependence. | Wang JC et al. | β | 2012 | β |
| The genetics of the opioid system and specific drug addictions. | Levran O et al. | β | 2012 | β |
| Zebrafish: a model for the study of addiction genetics. | Klee EW et al. | β | 2012 | β |
| ΞΊ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addiction. | Butelman ER et al. | β | 2012 | β |
| Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonment. | Kreek MJ | β | 2011 | β |
| Haplotype block structure of the genomic region of the mu opioid receptor gene. | Levran O et al. | β | 2011 | β |
| Impact of genetic polymorphisms in ABCB1, CYP2B6, OPRM1, ANKK1 and DRD2 genes on methadone therapy in Han Chinese patients. | Hung CC et al. | β | 2011 | β |
| Insight into pain-inducing and -related gene expression: a challenge for development of novel targeted therapeutic approaches. | Vasileiou I et al. | β | 2011 | β |
| Molecular mechanisms of opioid receptor-dependent signaling and behavior. | Al-Hasani R et al. | β | 2011 | β |
| Pharmacogenetic approaches to the treatment of alcohol addiction. | Heilig M et al. | β | 2011 | β |
| Pharmacogenomics of the human Β΅-opioid receptor. | Kasai S et al. | β | 2011 | β |
| Pilot study examining the frequency of several gene polymorphisms involved in morphine pharmacodynamics and pharmacokinetics in a morbidly obese population. | Lloret Linares C et al. | β | 2011 | β |
| Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases. | Zhou Y et al. | β | 2010 | β |
| Genetics of drug dependence. | Gelernter J et al. | β | 2010 | β |
| Neuropathic and chronic pain stimuli downregulate central mu-opioid and dopaminergic transmission. | Niikura K et al. | β | 2010 | β |
| OPRM1 and CYP2B6 gene variants as risk factors in methadone-related deaths. | Bunten H et al. | β | 2010 | β |
| OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models. | Mague SD et al. | β | 2010 | β |
| Overview and historical perspective of four papers presented on research related to the endogenous opioid system. | Kreek MJ | β | 2010 | β |
| Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. | Mroziewicz M et al. | β | 2010 | β |
| Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. | Khokhar JY et al. | β | 2010 | β |
| Pharmacotherapy in the treatment of addiction: methadone. | Kreek MJ et al. | β | 2010 | β |
| Search for genetic markers and functional variants involved in the development of opiate and cocaine addiction and treatment. | Yuferov V et al. | β | 2010 | β |
| Single-nucleotide polymorphism (A118G) in exon 1 of OPRM1 gene causes alteration in downstream signaling by mu-opioid receptor and may contribute to the genetic risk for addiction. | Deb I et al. | β | 2010 | β |
| Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. | Heilig M et al. | β | 2010 | β |
| Alterations of prodynorphin gene expression in the rat mesocorticolimbic system during heroin self-administration. | Solecki W et al. | β | 2009 | β |
| From taste hedonics to motivational drive: central ΞΌ-opioid receptors and binge-eating behaviour. | Nathan PJ et al. | β | 2009 | β |
| Genetic variants altering dopamine D2 receptor expression or function modulate the risk of opiate addiction and the dosage requirements of methadone substitution. | Doehring A et al. | β | 2009 | β |
| Increased OPRM1 DNA methylation in lymphocytes of methadone-maintained former heroin addicts. | Nielsen DA et al. | β | 2009 | β |
| Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRM1) and opioid dependence: A meta-analysis. | Coller JK et al. | β | 2009 | β |
| Opiate and cocaine addiction: from bench to clinic and back to the bench. | Kreek MJ et al. | β | 2009 | β |
| Polymorphism of the micro-opioid receptor gene (OPRM1 118A>G) affects fentanyl-induced analgesia during anesthesia and recovery. | Wu WD et al. | β | 2009 | β |
| Analgesic requirements after major abdominal surgery are associated with OPRM1 gene polymorphism genotype and haplotype. | Hayashida M et al. | β | 2008 | β |
| Candidate gene polymorphisms predicting individual sensitivity to opioids. | Kasai S et al. | β | 2008 | β |
| Genotype patterns that contribute to increased risk for or protection from developing heroin addiction. | Nielsen DA et al. | β | 2008 | β |
| Mood and neuroendocrine response to a chemical stressor, metyrapone, in buprenorphine-maintained heroin dependence. | Kakko J et al. | β | 2008 | β |
| Opioid neuropeptide genotypes in relation to heroin abuse: dopamine tone contributes to reversed mesolimbic proenkephalin expression. | Nikoshkov A et al. | β | 2008 | β |
| Role of a functional human gene polymorphism in stress responsivity and addictions. | Kreek MJ | β | 2008 | β |
| Substance dependence low-density whole genome association study in two distinct American populations. | Yu Y et al. | β | 2008 | β |
| The neural circuitry underlying reinstatement of heroin-seeking behavior in an animal model of relapse. | Rogers JL et al. | β | 2008 | β |
| The OPRD1 and OPRK1 loci in alcohol or drug dependence: OPRD1 variation modulates substance dependence risk. | Zhang H et al. | β | 2008 | β |
| Evaluation of OPRM1 variants in heroin dependence by family-based association testing and meta-analysis. | Glatt SJ et al. | β | 2007 | β |
| The opioid system in alcohol and drug dependence: family-based association study. | Xuei X et al. | β | 2007 | β |
| The single nucleotide polymorphism A118G alters functional properties of the human mu opioid receptor. | Kroslak T et al. | β | 2007 | β |
| Toward a rational selection of treatment for addiction. | O'Brien CP | β | 2007 | β |
| Treatment of addiction in the era of genomic medicine. | O'Brien C | β | 2007 | β |
| Altered levels of basal cortisol in healthy subjects with a 118G allele in exon 1 of the Mu opioid receptor gene. | Bart G et al. | β | 2006 | β |
| An overview of the genetics of substance use disorders. | Lachman HM | β | 2006 | β |
| Association between two mu-opioid receptor gene (OPRM1) haplotype blocks and drug or alcohol dependence. | Zhang H et al. | β | 2006 | β |
| Association of an Asn40Asp (A118G) polymorphism in the mu-opioid receptor gene with substance dependence: a meta-analysis. | Arias A et al. | β | 2006 | β |
| Genomewide linkage scan for opioid dependence and related traits. | Gelernter J et al. | β | 2006 | β |
| Linkage disequilibrium and association with methamphetamine dependence/psychosis of mu-opioid receptor gene polymorphisms. | Ide S et al. | β | 2006 | β |
| Mu opioid receptor A118G polymorphism in association with striatal opioid neuropeptide gene expression in heroin abusers. | Drakenberg K et al. | β | 2006 | β |
| Perspectives on current directions in the neurobiology of addiction disorders relevant to genetic risk factors. | Hurd YL | β | 2006 | β |
| Pharmacogenetics of opioid receptors and addiction. | Mayer P et al. | β | 2006 | β |
| Symbiotic relationship of pharmacogenetics and drugs of abuse. | Rutter JL | β | 2006 | β |
| Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. | Zhang Y et al. | β | 2005 | β |
| Clock reset for alcoholism. | Yuferov V et al. | β | 2005 | β |
| Genetic influences on impulsivity, risk taking, stress responsivity and vulnerability to drug abuse and addiction. | Kreek MJ et al. | β | 2005 | β |
| Increased attributable risk related to a functional mu-opioid receptor gene polymorphism in association with alcohol dependence in central Sweden. | Bart G et al. | β | 2005 | β |
| Microarray studies of psychostimulant-induced changes in gene expression. | Yuferov V et al. | β | 2005 | β |
| Neurobiology of addiction: treatment and public policy ramifications. | Dackis C et al. | β | 2005 | β |
| Pharmacogenetics and human molecular genetics of opiate and cocaine addictions and their treatments. | Kreek MJ et al. | β | 2005 | β |
| Evolving perspectives on neurobiological research on the addictions: celebration of the 30th anniversary of NIDA. | Kreek MJ et al. | β | 2004 | β |